Geloplasma Balance (Solution) Instructions for Use
Marketing Authorization Holder
Fresenius Kabi Deutschland, GmbH (Germany)
Manufactured By
Fresenius Kabi France (France)
ATC Code
B05AA06 (Gelatin preparations)
Active Substance
Gelatin (Ph.Eur. European Pharmacopoeia)
Dosage Form
| Geloplasma Balance | Infusion solution 3%: bags 500 ml 15 pcs. |
Dosage Form, Packaging, and Composition
Solution for infusion 3% transparent, colorless or light yellow in color.
| 1 L | |
| Gelatin (in the form of modified fluid gelatin*) | 30 g |
| Ionic composition: Sodium 150 mEq/L (corresponds to 150 mmol/L) Potassium 5 mEq/L (corresponds to 5 mmol/L) Magnesium 3 mEq/L (corresponds to 1.5 mmol/L) Chloride 100 mEq/L (corresponds to 100 mmol/L) Lactate 30 mEq/L (corresponds to 30 mmol/L) Osmolality 295 mOsm/kg |
|
* partially hydrolyzed and succinylated Gelatin.
Excipients : sodium chloride – 5.382 g, magnesium chloride hexahydrate – 0.305 g, potassium chloride – 0.373 g, sodium lactate solution (calculated as anhydrous sodium lactate) – 3.36 g, water for injections – up to 1 L.
500 ml – plastic two-layer polyvinyl chloride bags (15) – cardboard boxes.
Clinical-Pharmacological Group
Plasma substitute
Pharmacotherapeutic Group
Plasma substitute
Pharmacological Action
Plasma-substituting medicinal product. It increases the circulating blood volume, which leads to an increase in venous return and cardiac output, an increase in blood pressure, and an improvement in the perfusion of peripheral tissues.
The increase in circulating blood volume and the rise in blood pressure occur not only due to the administered solution but also due to the additional influx of interstitial fluid into the vascular bed.
By causing osmotic diuresis, it helps maintain kidney function during shock. It reduces blood viscosity and improves microcirculation.
Due to its colloid-osmotic properties, it prevents or reduces the likelihood of developing interstitial edema. It does not impair the protein, carbohydrate, or pigment functions of the liver; improves microcirculation; accelerates the erythrocyte sedimentation rate, which normalizes on average after 20 days.
The volume-replacing effect lasts for 5 hours.
Pharmacokinetics
It rapidly leaves the bloodstream, which is explained by the presence of a large number of low-molecular-weight fractions (after 2 hours, about 20% of the administered drug remains in the blood).
The elimination half-life is 9 hours. 75% of the administered substance is excreted by the kidneys, 15% through the intestines.
10% of the gelatin is broken down in the tissues through proteolysis and is included in protein metabolism. It does not accumulate.
Indications
Prevention and treatment of hypovolemia in cases of traumatic, burn, hemorrhagic, and toxic shock; conditions accompanied by blood thickening (for the purpose of hemodilution); extracorporeal circulation; prevention of blood pressure decrease during spinal or epidural anesthesia.
As a solvent for insulin administration (to reduce its losses due to adsorption on the walls of infusion containers and tubes).
ICD codes
| ICD-10 code | Indication |
| A48.3 | Toxic shock syndrome |
| E86 | Volume depletion (including dehydration, hypovolemia) |
| R57.1 | Hypovolemic shock |
| R57.8 | Other types of shock |
| R70.1 | Abnormality of plasma [blood] viscosity |
| T79.4 | Traumatic shock |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 1C45.Z | Toxic shock syndrome without specification of infectious agent |
| 5C70.Z | Decrease of volume of fluid [hypovolemia], unspecified |
| MA1A.1 | Abnormality of blood plasma viscosity |
| MG40.1 | Hypovolemic shock |
| MG40.Z | Shock, unspecified |
| NF0A.4 | Traumatic shock, not elsewhere classified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The dosage regimen is established individually, taking into account the severity of the plasma volume deficit.
It should be administered intravenously by drip. The duration of infusion and the volume of the administered solution are determined based on the dynamics of heart rate, blood pressure, diuresis, and the state of peripheral tissue perfusion.
For moderate blood loss and for prophylactic purposes in the preoperative period or during surgery, it is administered in a dose of 0.5-1 L over 1-3 hours.
For the treatment of severe hypovolemia – 1-2 L.
In emergency, life-threatening situations, 500 ml is administered as a rapid infusion (under pressure), then after improvement of circulation parameters, the infusion is continued in an amount equivalent to the volume deficit.
For maintaining circulating blood volume in shock, the infusion volume can reach 10-15 L/day.
For extracorporeal circulation, 0.5-1.5 L of solution is required (depending on the system used).
Adverse Reactions
From the cardiovascular system hypocoagulation, caused by a dilution effect (with a large infusion volume).
Allergic reactions anaphylactoid reactions.
Contraindications
Hypervolemia, severe chronic heart failure, hypersensitivity to gelatin.
Use with caution in cases of hyperhydration, chronic renal failure, hemorrhagic diathesis, pulmonary edema, hypokalemia, hyponatremia.
Use in Pregnancy and Lactation
The use of the drug during pregnancy and lactation is only possible if the intended benefit to the mother outweighs the potential risk to the fetus and child.
Use in Renal Impairment
Use with caution in cases of chronic renal failure.
Geriatric Use
The degree of hematocrit reduction after administration of the drug should not exceed 25% in elderly patients.
Special Precautions
The administration of gelatin may alter the parameters of diagnostic tests for glucose, fructose, cholesterol, fatty acids, as well as the erythrocyte sedimentation rate, specific gravity of urine, and urine protein indicators (including the biuret method).
When more than 2-3 L of solution is administered during surgery, the serum protein concentration should be monitored in the postoperative period, especially in the presence of tissue edema (if necessary, for further plasma-substituting therapy, the administration of human albumin is advisable).
The degree of hematocrit reduction after administration of the drug should not exceed 25% (in elderly patients, as well as in cases of cardiovascular and pulmonary insufficiency – 30%).
In chronic heart failure, the infusion should be performed slowly due to the possible circulatory overload.
When used as a pressure infusion (blood pressure cuff, infusion pump), the solution must be warmed to body temperature. When administering the drug under pressure, all air from the bottle should be removed beforehand.
Drug Interactions
Pharmaceutically incompatible with fat emulsions, barbiturates, muscle relaxants, antibiotics, glucocorticosteroids. Compatible with electrolyte solutions, carbohydrates, whole blood preparations.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Noopept, pills 10mg, 50pcs
No-spa pills 40mg, 64pcs
Daivobet, ointment, 30g
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Arbidol, capsules 100mg, 40pcs
Picamilon pills 50mg, 60pcs
Cortexin, 10mg, 5ml, 10pcs
Phenibut-Vertex pills 250mg, 20pcs
Belosalic, lotion solution for external use spray 100ml
Fenotropil pills 100mg, 60pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, ointment, 30g
Ingavirin capsules 90mg, 10pcs
OKI, sachets 80mg 2g, 12pcs
Nootropil pills 800mg, 30pcs 